Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Last Close
15.81
Nov 20 • 3:59 PM ET Dollar change-0.11 Percentage change(-0.69%)
Aftermarket Close
15.81
Aftermarket • 7:30 PM ET Dollar change0.00 Percentage change(0.00%)
Index
-
Market Cap
988.15M
Enterprise Value
-
Income
-
Sales
-
Book/sh
-
Cash/sh
-
Employees
-
IPO
Jan 29, 2020
P/E
-
Forward P/E
-
PEG
-
P/S
-
P/B
-
P/C
-
P/FCF
-
EV/EBITDA
-
EV/Sales
-
Quick Ratio
-
Current Ratio
-
Debt/Eq
-
LT Debt/Eq
-
Option/Short
No / Yes
EPS (ttm)
-
EPS next Y
-
EPS next Q
-
EPS this Y
-
EPS next Y
-
EPS next 5Y
-
EPS past 3/5Y
- -
Sales past 3/5Y
- -
EPS Y/Y TTM
-
Sales Y/Y TTM
-
EPS Q/Q
-
Sales Q/Q
-
Earnings
-
EPS/Sales Surpr.
- -
Insider Own
0.02%
Insider Trans
-
Inst Own
28.16%
Inst Trans
-
ROA
-
ROE
-
ROIC
-
Gross Margin
-
Oper. Margin
-
Profit Margin
-
SMA20
-7.90%
SMA50
-5.92%
SMA200
2.40%
Trades
Shs Outstand
62.50M
Shs Float
62.49M
52W High
17.96 -11.97%
52W Low
13.70 15.40%
Volatility
3.55% 2.36%
ATR (14)
0.41
RSI (14)
30.37
Beta
0.88
Rel Volume
1.33
Avg Volume
159.00K
Volume
212,083
Perf Week
-7.97%
Perf Month
-5.78%
Perf Quarter
-6.06%
Perf Half Y
11.50%
Perf YTD
5.05%
Perf Year
8.21%
Perf 3Y
14.65%
Perf 5Y
-38.13%
Perf 10Y
-
Recom
-
Target Price
-
Prev Close
15.92
Price
15.81
Change %
-0.69%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Fairbairn Robert WDirectorDec 18 '25Sale14.9810,294154,2040Dec 22 05:29 PM
Fairbairn Robert WDirectorDec 18 '25Sale14.9810,294154,2040Dec 22 05:29 PM
Fairbairn Robert WDirectorDec 19 '25Sale14.96060Dec 22 05:29 PM
Fairbairn Robert WDirectorDec 19 '25Sale14.96060Dec 22 05:29 PM
BlackRock Health Sciences Trust II's (BMEZ) investment objective is to provide total return and income through a combination of current income, current gains and long-term capital appreciation. The Trust seeks to achieve its investment objective by investing, under normal market conditions, at least 80% of its total assets in equity securities of companies principally engaged in the health sciences group of industries and equity derivatives with exposure to the health sciences group of industries. The Trust utilizes an option writing (selling) strategy in an effort to generate current gains from options premiums and to enhance the Trust's risk-adjusted returns.
Portfolio ManagerDr. Xiang Liu Ph.D.